Rockwell Medical (RMTI) Amortization of Deferred Charges (2013 - 2026)
Rockwell Medical's (RMTI) quarterly Amortization of Deferred Charges came in at $88000.0 in Q1 2026, little changed YoY from $88000.0 in Q1 2025, and down 1.12% on a QoQ basis from $89000.0 in Q4 2025.
Rockwell Medical (RMTI) Amortization of Deferred Charges (2013 - 2026) Analysis & Trends
Rockwell Medical (RMTI) has 9 years of Amortization of Deferred Charges data on file, last reported at $88000.0 in Q1 2026.
- Quarterly Amortization of Deferred Charges changed 0.0% year-over-year to $88000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $354000.0 (up 20.0% YoY) and the FY2025 annual result came in at $354000.0, down 16.9% from the prior year.
- Amortization of Deferred Charges retreated to $88000.0 in Q1 2026, from $89000.0 in the prior quarter.
- In the past five years, Amortization of Deferred Charges ranged from a high of $831000.0 in Q4 2023 to a low of $30000.0 in Q2 2024.
- A 5-year average of $137882.4 and a median of $92000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- Annual changes were most pronounced in 2022 — Amortization of Deferred Charges slumped 94.08% — and 2023, when it jumped 793.55%.
- Tracing RMTI's Amortization of Deferred Charges over 5 years: stood at $93000.0 in 2022, then jumped by 793.55% to $831000.0 in 2023, then tumbled by 89.29% to $89000.0 in 2024, then changed by 0.0% to $89000.0 in 2025, then declined by 1.12% to $88000.0 in 2026.
- The last three Amortization of Deferred Charges figures came in at $88000.0 (Q1 2026), $89000.0 (Q4 2025), and $89000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.96 Bn | 43.00 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.23 Bn | 39.58 Bn | 2.15 Bn |
| 3 | Zoetis | 31.76 Bn | 30.08 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.68 Bn | 22.88 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.27 Bn | 19.61 Bn | 683.80 Mn |
| 6 | Viatris | 18.69 Bn | 17.81 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.56 Bn | 15.17 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.78 Bn | 11.25 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.13 Bn | 9.97 Bn | - |
| 10 | Rockwell Medical | 29.77 Mn | 4.98 Mn | 3.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 90,000.00 |
| Jun 30, 2026 | 90,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Mar 31, 2026 | 88,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Dec 31, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Sep 30, 2025 | 89,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Jun 30, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Mar 31, 2025 | 88,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Dec 31, 2024 | 89,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Sep 30, 2024 | 88,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Jun 30, 2024 | 30,000.00 |
| Mar 31, 2024 | 219,000.00 |
| Mar 31, 2024 | 219,000.00 |